172 related articles for article (PubMed ID: 32781600)
21. Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.
Parta M; Kelly C; Kwatemaa N; Theobald N; Hilligoss D; Qin J; Kuhns DB; Zerbe C; Holland SM; Malech H; Kang EM
J Clin Immunol; 2017 Aug; 37(6):548-558. PubMed ID: 28752258
[TBL] [Abstract][Full Text] [Related]
22. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
Saito B; Fukuda T; Yokoyama H; Kurosawa S; Takahashi T; Fuji S; Takahashi N; Tajima K; Kim SW; Mori SI; Tanosaki R; Takaue Y; Heike Y
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1148-1155. PubMed ID: 18804045
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
24. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
Boelens JJ; Aldenhoven M; Purtill D; Ruggeri A; Defor T; Wynn R; Wraith E; Cavazzana-Calvo M; Rovelli A; Fischer A; Tolar J; Prasad VK; Escolar M; Gluckman E; O'Meara A; Orchard PJ; Veys P; Eapen M; Kurtzberg J; Rocha V; ; ; ;
Blood; 2013 May; 121(19):3981-7. PubMed ID: 23493783
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
27. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
29. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
30. The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis.
Qu Y; Liu H; Wei L; Nie S; Ding W; Liu S; Liu H; Jiang H
Front Pediatr; 2022; 10():877735. PubMed ID: 35844734
[TBL] [Abstract][Full Text] [Related]
31. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.
Peters C; Balthazor M; Shapiro EG; King RJ; Kollman C; Hegland JD; Henslee-Downey J; Trigg ME; Cowan MJ; Sanders J; Bunin N; Weinstein H; Lenarsky C; Falk P; Harris R; Bowen T; Williams TE; Grayson GH; Warkentin P; Sender L; Cool VA; Crittenden M; Packman S; Kaplan P; Lockman LA; Anderson J; Krivit W; Dusenbery K; Wagner J
Blood; 1996 Jun; 87(11):4894-902. PubMed ID: 8639864
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies.
Bramanti S; De Philippis C; Bartoli A; Giordano L; Mariotti J; Sarina B; Mannina D; Valli V; De Gregori S; Roperti M; Pieri G; Castagna L
Transplant Cell Ther; 2021 Nov; 27(11):912.e1-912.e6. PubMed ID: 34403790
[TBL] [Abstract][Full Text] [Related]
33. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
[No Abstract] [Full Text] [Related]
34. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
35. [Allogeneic hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis type 1: a case report].
Ou RM; Wang L; Zheng LL; Yao MD; Jiang WT; Zhou CH
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):181-3. PubMed ID: 16787585
[TBL] [Abstract][Full Text] [Related]
36. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
Behfar M; Dehghani SS; Hosseini AS; Jalali A; Hamidieh AA; Ghavamzadeh A
Pediatr Transplant; 2015 Jun; 19(4):422-7. PubMed ID: 25879376
[TBL] [Abstract][Full Text] [Related]
37. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.
Felber M; Steward CG; Kentouche K; Fasth A; Wynn RF; Zeilhofer U; Haunerdinger V; Volkmer B; Prader S; Gruhn B; Ehl S; Lehmberg K; Müller D; Gennery AR; Albert MH; Hauck F; Rao K; Veys P; Hassan M; Lankester AC; Schmid JP; Hauri-Hohl MM; Güngör T
Blood Adv; 2020 May; 4(9):1998-2010. PubMed ID: 32384542
[TBL] [Abstract][Full Text] [Related]
38. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
[TBL] [Abstract][Full Text] [Related]
39. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.
Boelens JJ; Rocha V; Aldenhoven M; Wynn R; O'Meara A; Michel G; Ionescu I; Parikh S; Prasad VK; Szabolcs P; Escolar M; Gluckman E; Cavazzana-Calvo M; Kurtzberg J;
Biol Blood Marrow Transplant; 2009 May; 15(5):618-25. PubMed ID: 19361754
[TBL] [Abstract][Full Text] [Related]
40. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Slatter MA; Rao K; Amrolia P; Flood T; Abinun M; Hambleton S; Nademi Z; Goulden N; Davies G; Qasim W; Gaspar HB; Cant A; Gennery AR; Veys P
Blood; 2011 Apr; 117(16):4367-75. PubMed ID: 21325599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
